Favipiravir Shows 50% Mortality Reduction in First Randomized Lassa Fever Trial in Four Decades
Key Insights
A Phase 2 randomized controlled trial published in Nature Medicine demonstrates favipiravir achieved a hazard ratio of 0.50 for mortality compared to ribavirin in Lassa fever (search) patients, representing a 50% reduction in death risk.
The SAFARI trial marks the first regulatory-compliant randomized controlled clinical trial evaluating a new Lassa fever (search) treatment in 40 years, conducted in Nigeria's highest-transmission regions with 41 participants.
All study participants survived and were successfully discharged, with favipiravir showing better tolerability than ribavirin, particularly reduced anemia (search) risk which required blood transfusion in one ribavirin patient.
A landmark Phase 2 randomized controlled trial has demonstrated that favipiravir significantly reduces mortality risk in Lassa fever (search) patients compared to the current standard of care, ribavirin. The SAFARI trial, published in Nature Medicine, achieved a hazard ratio of 0.50 for mortality in the favipiravir arm, representing a 50% reduction in death risk—the first such evidence from a properly controlled trial in four decades of Lassa fever treatment.
Breakthrough Results After Decades of Uncertain Evidence
The trial enrolled 41 participants across two major Nigerian treatment centers between August 2021 and October 2022, with 21 randomized to ribavirin and 20 to favipiravir. Remarkably, all participants survived and were successfully discharged, marking a significant achievement in a disease where case fatality rates among hospitalized patients reached 16.3% in Nigeria in 2024 according to WHO data.
"This study constitutes a regulatory-compliant, randomized controlled clinical trial evaluating a new treatment for LF, which has not been done for the past four decades," the researchers noted, emphasizing the landmark nature of conducting such a trial in West Africa's highest-transmission regions.
The results directly challenge ribavirin's entrenched position as standard care. A 2022 systematic review covering all published and unpublished data through March 2022 concluded that "robust evidence supporting the use of ribavirin in Lassa fever (search) is lacking," with the foundational 1986 McCormick study lacking the controls and sample sizes modern methodology would require.
Superior Safety Profile Addresses Critical Treatment Gap
Beyond mortality benefits, favipiravir demonstrated superior tolerability compared to ribavirin, particularly regarding anemia (search)—a major complication of ribavirin therapy that poses additional risks in hemorrhagic fever (search) patients. Anemia was the most common drug-related adverse event in the ribavirin group, affecting 36% of participants, compared to only 6% in the favipiravir group.
One participant receiving ribavirin required blood transfusion due to life-threatening anemia (search), with hemoglobin levels dropping from 13.0 g/dL at baseline to 7.5 g/dL by day 8. This 62-year-old woman received 7 units of erythrocyte concentrate and had a hospital stay of 23 days—the longest in the study. In contrast, no participant in the favipiravir arm had a hospital stay longer than 10 days.
"The lower propensity of favipiravir to induce anemia (search) reinforces its relevance as a more tolerable treatment option, constituting a clinically relevant advantage in the treatment of patients with LF as they have already a substantial risk for chronic or acute bleeding," the researchers emphasized.
Pharmacokinetic Insights Enable Optimized Dosing
The trial provided crucial pharmacokinetic data for favipiravir in Lassa fever (search) patients, with drug exposure remaining consistently above estimated effective concentrations throughout treatment. Body weight emerged as a significant covariate affecting favipiravir clearance, with higher weight correlating with increased clearance.
Based on pharmacokinetic modeling, researchers proposed an optimized dosing regimen for future trials: 2,400 mg twice daily on day 1 followed by 1,600 mg twice daily from days 2-10. This refined approach aims to reduce peak plasma concentrations potentially associated with adverse reactions while maintaining therapeutic efficacy.
The study regimen achieved 98% time above half-maximal inhibitory concentration within the first day, with the percentage of time above 90% and 99% inhibitory concentrations reaching 98% and 97.5% respectively, supporting the adequacy of the investigated dosing approach.
Regulatory Pathway Challenges Ahead
Despite the compelling efficacy signal, the path to regulatory approval faces significant challenges. The open-label design, while appropriate for the endemic setting, may complicate FDA review processes. However, mortality represents an objective, binary endpoint that mitigates some concerns about open-label bias.
The FDA's Tropical Disease Priority Review pathway applies to Lassa fever (search), potentially expediting review timelines. However, whether Phase 2 mortality data from an open-label trial in a West African endemic setting satisfies FDA requirements for approval, or whether a Phase 3 confirmatory trial is necessary, remains an open question.
Given Lassa fever (search)'s seasonal and geographic concentration, a Phase 3 trial could require multi-site enrollment across several West African countries over multiple seasonal cycles, potentially taking a decade to complete. This timeline reality may favor regulatory pathways like Accelerated Approval, using Phase 2 mortality data as reasonably likely to predict clinical benefit.
Implications for Future Lassa Fever Treatment
The results fundamentally alter the landscape for future Lassa fever (search) therapeutic development. Any subsequent trials using ribavirin as an active control must now contend with published evidence of favipiravir's superiority, potentially affecting ethics committee approvals for ribavirin-controlled studies.
The trial's success also validates the feasibility of conducting rigorous clinical research in endemic hemorrhagic fever (search) zones, despite operational challenges including narrow enrollment windows, complex informed consent processes, and supply chain logistics in resource-limited settings.
"The further clinical development of favipiravir is currently underway in a large platform trial that aims to identify the next generation of direct antiviral and adjunct treatments for LF," the researchers noted, referencing the ongoing INTEGRATE trial that will evaluate treatments across regions where different LASV lineages circulate.
This breakthrough represents not just a potential new treatment option, but a methodological achievement demonstrating that high-quality randomized controlled trials can be conducted in challenging endemic settings, potentially paving the way for evidence-based treatment guidelines in Lassa fever (search) for the first time in four decades.